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background: The NLRP3 inflammasome is a key amplifier of the inflammatory response during acute myocardial infarction. The NLRP3 
inflammasome activates caspase-1, generates mature Interleukin-1beta and promotes tissue damage. We have recently developed a new 
compound, 16673-34-0, showing its ability to inhibit the NLRP3 inflammasome in vitro and in vivo. The aim of this study was to test the efficacy of 
16673-34-0 in myocardial ischemia reperfusion injury with the drug given at time of reperfusion.
methods: Adult male CD-1 mice underwent ischemia (30’) followed by reperfusion (24 hours) or sham operation. A single dose of 16673-34-0 
(100 mg/kg) was administered intraperitoneally at time of reperfusion. Other 2 groups of mice were treated with 0.9% NaCl or the vehicle (5% of 
di-methyl-sulfoxide/95% poly-ethylene-glycol). At 24 hours, infarct size was measured using tri-phenyl-tetrazolium-chloride and caspase-1 activity 
was measured with a fluorometric assay to detect inflammasome activation and compared 16673-34-0 to the vehicle.
results: Twentyfour hours following treatment, 16673-34-0 significantly reduced the infarct size as compared to the controls (Figure). This results 
were corroborated by a strong reduction of the caspase-1 activity measured in the hearts compared to the controls (Figure).
Conclusion: The newly developed NLRP3 inflammasome inhibitor 16673-34-0 significantly reduces infarct size when given at reperfusion in a 
mouse model of myocardial ischemia-reperfusion injury.
 
